Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease

Investigation of the Relationship Between Sleep Quality, Cognitive Functions, and Disease Severity in Patients With Parkinson's Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07536490

Enrollment

Registered

2026-04-17

Start date

2026-05-10

Completion date

2026-06-10

Last updated

2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson Disease, Sleep Quality, Cognitive Function, Disease Severity

Brief summary

The goal of this observational study is to investigate the relationship between sleep quality, cognitive functions, and disease severity in individuals with Parkinson's disease. The main question it aims to answer is: Is sleep quality associated with cognitive function and disease severity in individuals with Parkinson's disease? Participants will complete assessments of sleep quality, cognitive function, disease severity, and disease stage during a single evaluation session. Cognitive function will be evaluated using the Stroop Test, Clock Drawing Test, and Montreal Cognitive Assessment. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale, and disease stage will be determined using the Modified Hoehn and Yahr Scale.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age between 40 and 65 years * Diagnosis of Parkinson's disease confirmed by a neurologist * Modified Hoehn and Yahr stage between 1 and 3 * Montreal Cognitive Assessment (MoCA) score ≥21

Exclusion criteria

* Difficulty in verbal communication * Use of walking aid * Severe visual impairment or additional neurological disorder * Presence of congestive heart failure * Any medical condition preventing participation

Design outcomes

Primary

Measure	Time frame	Description
Sleep Quality	Baseline	Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.
Stroop Test	Baseline	Cognitive flexibility and selective attention will be assessed using the Stroop Test. Completion time and error rates will be recorded, with longer times and higher error rates indicating poorer performance. Time Frame: Baseline
Clock Drawing Test	Baseline	Visuospatial ability and executive function will be assessed using the Clock Drawing Test. Scores will be recorded based on standard scoring criteria, with lower scores indicating impaired performance.
Disease Severity	Baseline	Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale. Higher scores indicate greater disease severity.

Secondary

Measure	Time frame	Description
Montreal Cognitive Assessment	Baseline	Global cognitive function will be assessed using the Montreal Cognitive Assessment. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment.
Disease Stage	Baseline	Disease stage will be determined using the Modified Hoehn and Yahr Scale. Higher stages indicate more advanced disease.

Countries

Turkey (Türkiye)

Contacts

STUDY_CHAIRSüleyman Korkusuz

Atılım University

STUDY_CHAIRAyla Fil

Hacettepe University

STUDY_CHAIRGül Yalçın Çakmaklı